Diabetic Peripheral Neuropathic Pain: key endpoint results by drug
The key endpoints of Diabetic Peripheral Neuropathic Pain trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Diabetic Peripheral Neuropathic Pain page.
Average daily pain, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Duloxetine | -3.1 | -2.6 (Pregabalin) | — | wk 12 · n 120 | NCT00385671 Phase 4, secondary |
| Eslicarbazepine acetate | -1.8 | -1.6 | −0.2 | 1200 mg QD · wk 17 · n 85 | NCT00980746 Phase 2, primary |
| Gabapentin | -3.1 | -2.6 (Pregabalin) | — | wk 12 · n 120 | NCT00385671 Phase 4, secondary |
| Mirogabalin | -1.8 | -1.5 | −0.2 | 30 mg/Day · wk 7 · n 90 | NCT01504412 Phase 2, primary |
| Nabiximols | -1.7 | -1.6 | −0.1 | wk 14 · n 146 | NCT00710424 Phase 3, primary |
| Perampanel | -1.9 | -2.5 | +0.6 | 8 mg · wk 12 · n 70 | NCT00505284 Phase 2/3, primary |
| Pregabalin | -1.3 | -0.9 | −0.4 | wk 8 · n 161 | NCT00141219 Phase 3, secondary |
| Suzetrigine | -2.2 | -2.1 (Pregabalin) | — | Low Dose · wk 12 · n 24 | NCT05660538 Phase 2, primary |
| Tapentadol | -2.6 | -2.6 | ±0 | wk 12 · n 60 | NCT01124617 Phase 2, primary |
Drugs checked with no result here: 14 not reported, 2 not posted, 1 trial running.
30% pain reduction
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Duloxetine | 56.7% | 51.2% (Pregabalin) | — | wk 12 · n 120 | NCT00385671 Phase 4, secondary |
| Gabapentin | 56.7% | 51.2% (Pregabalin) | — | wk 12 · n 120 | NCT00385671 Phase 4, secondary |
| Nabiximols | 36.2% | 39.9% | −3.7 | wk 14 · n 149 | NCT00710424 Phase 3, primary |
| Pregabalin | 50.3% | 44.3% | +6 | wk 9 · n 312 | NCT01332149 Phase 3, secondary |
| Suzetrigine | 70.8% | 44.9% (Pregabalin) | — | Low Dose · wk 12 · n 24 | NCT05660538 Phase 2, secondary |
Drugs checked with no result here: 17 not reported, 3 not posted, 1 trial running.
50% pain reduction
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Duloxetine | 41.7% | 37.8% (Pregabalin) | — | wk 12 · n 120 | NCT00385671 Phase 4, secondary |
| Gabapentin | 41.7% | 37.8% (Pregabalin) | — | wk 12 · n 120 | NCT00385671 Phase 4, secondary |
| Pregabalin | 26.1% | 14.3% | +11.8 | wk 8 · n 161 | NCT00141219 Phase 3, secondary |
| Suzetrigine | 41.7% | 22.4% (Pregabalin) | — | Low Dose · wk 12 · n 24 | NCT05660538 Phase 2, secondary |
| Tapentadol | 40.4% | 28.9% | +11.5 | wk 15 · n 166 | NCT01041859 Phase 3, secondary |
Drugs checked with no result here: 17 not reported, 3 not posted, 1 trial running.
Sleep interference, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Lacosamide | -1.8 | -1.6 | −0.2 | 400 mg/day · wk 16 · n 186 | NCT00350103 Phase 3, secondary |
| Perampanel | -1.1 | -2.2 | +1 | 8 mg · wk 15 · n 70 | NCT00505284 Phase 2/3, secondary |
| Pregabalin | -1.4 | -0.7 | −0.6 | 600 mg/day · wk 13 · n 45 | NCT00553475 Phase 3, secondary |
| Suzetrigine | -2.2 | -2.4 (Pregabalin) | — | Low Dose · wk 12 · n 24 | NCT05660538 Phase 2, secondary |
Drugs checked with no result here: 18 not reported, 3 not posted, 1 trial running.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 26 approved or late-stage drugs with a featured trial in Diabetic Peripheral Neuropathic Pain were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.